Similarly, another study suggested that antibiotic use was associated with reduced TKI efficacy in advanced melanoma and NSCLC [23], but the TKI cohort also included both EGFR and BRAF inhibitors, precluding class-specific conclusions. The gene discussed is EGFR; the disease is melanoma.